A Comprehensive Self-Management Programme For Chronic Obstructive Pulmonary Disease In The Community
Funder
National Health and Medical Research Council
Funding Amount
$391,610.00
Summary
Chronic obstructive pulmonary disease (COPD) is the third leading cause of burden of disease in Australia. It has a major impact on sufferers, their carers and society. This study introduces a new model of community care, based on case management, mentoring to improve self-efficacy and information systems to deliver information and closely monitor disease status. This will improve the quality of life of sufferers, develop healthcare networks and decrease healthcare utilisation.
Surfactant Protein D As A Candidate Therapy In COPD
Funder
National Health and Medical Research Council
Funding Amount
$405,749.00
Summary
Smoking -related chronic bronchitis and emphysema, otherwise known COPD, costs the healthcare system over $800 million per year. People continue to suffer even after they have given up smoking, and the treatments available result in only modest improvements. COPD is associated with a a defect of the scavenging cells in the lung, which normally clear away dying cells, and some of the proteins ivolved in this process. We will investigate whether supplementing these proteins will help.
Preventing Complications Of Chronic Obstructive Pulmonary Disease
Funder
National Health and Medical Research Council
Funding Amount
$310,914.00
Summary
Chronic obstructive pulmonary disease (COPD) is a devastating lung disease that affects smokers. Lung complications and complications in other organs occur commonly. This study will examine factors that lead to exacerbations of COPD, and test the effectiveness of early diagnosis of coronary artery disease using CT scans.
The Role Of Apoptosis And Macrophage Function In Chronic Obstructive Pulmonary Disease
Funder
National Health and Medical Research Council
Funding Amount
$463,400.00
Summary
Chronic obstructive pulmonary disease (COPD) is a complex, chronic disease of the lungs principally caused by cigarette smoking. COPD is very common and causes a great deal of debility and mortality in our community. COPD is also linked to an increased risk of lung cancer and carviovascular disease. It is estimated to cost Australians at least $800 million dollars per year in health related costs. Despite its importance, there is a limited understanding of how COPD develops and treatment options ....Chronic obstructive pulmonary disease (COPD) is a complex, chronic disease of the lungs principally caused by cigarette smoking. COPD is very common and causes a great deal of debility and mortality in our community. COPD is also linked to an increased risk of lung cancer and carviovascular disease. It is estimated to cost Australians at least $800 million dollars per year in health related costs. Despite its importance, there is a limited understanding of how COPD develops and treatment options are limited. We have identified large numbers of dying cells in the airways of people with COPD and we believe that these play a critical part in the cause and-or progression of the illness. This project will determine whether the increased rates of cell death are the result of the COPD process or part of the actual cause of the disease. This knowledge will enable us to address the urgent need to predict the risk of developing COPD in current and ex- smokers. Cells obtained from the lungs of healthy controls, current- ex smokers without COPD and current- ex smokers with COPD will be studied. The effects of current treatments for COPD on these cells as well as testing novel treatments will also be studied, paying particular attention to the effects on cell death. In this way we hope that new therapies will be identified to improve the health and well-being of those with COPD.Read moreRead less
Centre For Clinical Research Excellence In Respiratory And Sleep Medicine
Funder
National Health and Medical Research Council
Funding Amount
$2,200,000.00
Summary
The CCRE will enhance Australia's international research reputation in clinical respiratory and sleep medicine by enhancing links between hospital-based investigators. This will foster development of new clinical researchers in these fields. Major research projects will include reducing side effects of asthma therapy in the elderly, better and cheaper ways of diagnosing disorders such as sleep apnoea and blood clots in the lung, keeping patients with chronic lung diseases out of hospital and avo ....The CCRE will enhance Australia's international research reputation in clinical respiratory and sleep medicine by enhancing links between hospital-based investigators. This will foster development of new clinical researchers in these fields. Major research projects will include reducing side effects of asthma therapy in the elderly, better and cheaper ways of diagnosing disorders such as sleep apnoea and blood clots in the lung, keeping patients with chronic lung diseases out of hospital and avoiding accidents due to lack of sleep.Read moreRead less
Targeting Oxidant-dependent Pathways To Treat Skeletal Muscle Wasting In COPD
Funder
National Health and Medical Research Council
Funding Amount
$1,089,054.00
Summary
Chronic Obstructive Pulmonary Disease (COPD) is a major incurable global health burden and is the 4th largest cause of death worldwide. A significant proportion of COPD patients have skeletal muscle wasting and loss of strength which severely impacts on their quality of life and survival. The reason for this is unknown so the aim of this study is to determine how skeletal muscle wasting occurs in COPD and to then develop new medicines to treat skeletal muscle wasting and dysfunction in COPD.
Local SAA Production Drives Glucocortosteriod Resistant Airway Inflammation In COPD
Funder
National Health and Medical Research Council
Funding Amount
$540,704.00
Summary
We have recently identified a blood marker termed SAA that is highly elevated during an acute attack of Chronic Obstructive Pulmonary Disease (COPD) mainly caused by chest infections. These episodes are a major cause of hospitalisation. Our previous studies suggest that by measuring blood SAA levels we can prevent a worsening of the attack with early intervention. We are now exploring the biological role of SAA and whether blocking SAA activity will benefit COPD patients.